EyePoint vs Verrica Pharmaceuticals
Verrica Pharmaceuticals reported revenue of $36 million in fiscal 2025, about the same as EyePoint's $31 million in fiscal 2025. EyePoint's revenue fell 27.5% in its latest year, and Verrica Pharmaceuticals' grew 370.2%. EyePoint had an operating margin of -776.0%, against -34.2% at Verrica Pharmaceuticals. Free cash flow was −$243 million at EyePoint and −$18 million at Verrica Pharmaceuticals.
Side by side
| EyePoint | Verrica Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $31M | $36M |
| Revenue growth | −27.5% | 370.2% |
| Revenue growth a year, last 5 years | −1.8% | — |
| Gross margin | — | — |
| Operating margin | −776.0% | −34.2% |
| Net margin | −739.4% | −50.3% |
| Free cash flow | −$243M | −$18M |
| Free cash flow margin | −775.8% | −49.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 30.1% | 105.6% |
| Last close | $0.26 | $2.88 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $71,983, sold $0 | bought $18.2 million, sold $0 |
| Piotroski F-score | — | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EyePointVerrica Pharmaceuticals
Operating margin
Percent of revenue
EyePointVerrica Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EyePointVerrica Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the EyePoint and Verrica Pharmaceuticals pages.